Enhanced Dosage Forms of Tissue Kallikrein 1 for Ischemic Conditions

Improved dosage forms and systems for treating ischemic conditions using tissue kallikrein 1 polypeptides, offering enhanced efficacy, convenience, and personalized treatment.

The original patent disclosed dosage forms of tissue kallikrein 1 for treating ischemic conditions. However, the patent's limitations include the need for precise dosing, real-time monitoring, and tailored treatment approaches. The new inventive concept addresses these limitations by introducing advanced systems and dosage forms that provide precise dosing, real-time monitoring, and personalized treatment.

The new inventive concept comprises a system for treating ischemic conditions, including a portable injector programmed to deliver precise doses of KLK1 polypeptides based on a subject's physiological response. The system also includes a method for optimizing the dosage of KLK1 polypeptides in real-time, a sustained-release matrix for maintaining a therapeutically effective serum level, and a kit for personalized treatment. The kit includes a dosage form, a portable injector, and a monitoring device for tracking the subject's physiological response.

The new claims introduce novel elements, such as the portable injector, real-time monitoring, and sustained-release matrix, which are not present in the original patent. These elements provide a non-obvious solution to the limitations of the original patent, enabling more effective, convenient, and personalized treatment of ischemic conditions.

Alternative embodiments of the inventive concept could include variations in the portable injector design, different types of monitoring devices, and alternative sustained-release matrices. Additionally, the kit could be tailored to specific ischemic conditions, such as cardiac ischemia or limb ischemia.

The enhanced dosage forms and systems for treating ischemic conditions have significant commercial potential in the pharmaceutical and biotechnology industries. The target market includes hospitals, clinics, and medical research institutions, as well as patients suffering from ischemic conditions.